Genmab — Januar 2024
-
Tirsdagens danske avisuddrag med Vestas, Pandora og Genmab https://www.proinvestor.com/investornyt/1100847/tirsdagens-danske-avisuddrag-med-vestas-pandora-og-genmab
-
Kursmålet for Genmab sænkes med 14 pct. af canadisk finanshus https://www.proinvestor.com/investornyt/1100852/kursmalet-for-genmab-saenkes-med-14-pct-af-canadisk-finanshus
-
Novartis Strategy
& Growth Update
from
J.P. Morgan Healthcare Conference https://www.novartis.com/sites/novartis_com/files/2024-jpm-novartis-strategy-growth-update.pdf -
JPM24: As cancer players jump head-first into ADC field, Novartis CEO explains how he's resisted the temptation https://www.fiercepharma.com/pharma/jpm24-cancer-players-jump-head-first-adc-field-novartis-ceo-explains-how-hes-resisted
-
TIVDAK
(tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug https://www.proinvestor.com/investornyt/1100949/tivdak-tisotumab-vedotin-tftv-supplemental-biologics-license-application-accepted-for-priority-review-by-us-food-and-drug -
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference https://investors.biontech.de/news-releases/news-release-details/biontech-outlines-2024-strategic-priorities-42nd-annual-jp
-
"Based on emerging clinical data, the companies have planned engagement with health authorities on the design of a Phase 3 trial for BNT311/GEN1046 (acasunlimab) in second line NSCLC. The companies intend to share the data on which this decision was based at a medical conference in 2024."
-
Genmab tager skridt mod fuld godkendelse af middel mod livmoderhalskræft i USA https://www.proinvestor.com/investornyt/1100966/genmab-tager-skridt-mod-fuld-godkendelse-af-middel-mod-livmoderhalskraeft-i-usa
-
Godmorgen
-
EDITED TRANSCRIPT
JNJ.N - Johnson & Johnson at JPMorgan Healthcare Conference
JANUARY 08, 2024 https://www.investor.jnj.com/files/doc_events/2024/Jan/08/jnj-usq_transcript_2024-01-08-final.pdf -
BioNTech presentation @ J.P. Morgan
Healthcare Conference
Prof. Ugur Sahin, M.D.
9 January 2024 https://investors.biontech.de/static-files/91096519-e8d6-4f64-8c59-2f5557503fbf -->confirms HexaBody-OX40 is next , GEN1055 /
BNT315 -
as rumoured here on PI
- 6/12 12:37
af E L
ESMO Immuno-Oncology 2023 Poster online- HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo (link) "A first-in-human clinical trial is planned " I am assuming this is the #6 in the BioNTech cooperation. -
yes, i think an important worry for the analysts over the last 2, 3 years was; will the new drugs, Tec, Tal, Carvykti replace Dara, and time after time JNJ keep repeating it will not; it is complimentary. It is a shame they never give an estimate for peak sales for Dara though
-
GENMAB,
Success-story danoise https://www.strike-magazine.fr/genmab/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind